StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too

Because intismeran autogene is a personalized cancer therapy made for each patient based on the individual genetic mutations of their tumors, the Merck-Moderna stock surge extended to sequencing giants such as Illumina, PacBio of California, and to a degree Oxford Nanopore Technologies. The post StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too appeared…